We are live on ! Find out more
DC

Decheng Capital Portfolio holdings

AUM $661M
1-Year Est. Return 299.97%
This Fund
S&P 500
This Quarter Est. Return
-10.08%
1 Year Est. Return
+299.97%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$466M
AUM Growth
+$44M
Cap. Flow
+$133M
Cap. Flow %
28.46%
Top 10 Hldgs %
83.67%
Holding
30
New
4
Increased
10
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
UPB
Upstream Bio Inc
UPB
+$73.4M
2
CGON icon
CG Oncology
CGON
+$30.5M
3
LYEL icon
Lyell Immunopharma
LYEL
+$11.8M
4
RVMD icon
Revolution Medicines
RVMD
+$11.3M
5
ACRS icon
Aclaris Therapeutics
ACRS
+$5.64M

Top Sells

Rank Stock Value
1
PHAT icon
Phathom Pharmaceuticals
PHAT
+$6.88M
2
WGS icon
GeneDx Holdings
WGS
+$4.4M
3
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$2.52M
4
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$1.88M
5
RCUS icon
Arcus Biosciences
RCUS
+$996K

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PYXS icon
26
Pyxis Oncology
PYXS
$184M
$510K 0.11%
326,810
– –
GRAL
27
GRAIL Inc
GRAL
$2.76B
$173K 0.04%
9,684
– –
NUVB.WS
28
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$149K 0.03%
646,057
– –
WGS icon
29
GeneDx Holdings
WGS
$1.84B
– –
-103,604
Closed -$4.4M
LBPH
30
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
– –
-56,350
Closed -$1.88M
1
2

Similar funds

FAM
Fulcrum Asset Management London, United Kingdom $662M AUM 48.09% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
HIG
Heritage Investment Group Pompano Beach, Florida $661M AUM 14.84% 1-Year Est. Return
RCG
Regatta Capital Group El Segundo, California $661M AUM 17.85% 1-Year Est. Return
FM
Freemont Management Vaud, Switzerland $661M AUM 60.48% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
AWA
Artemis Wealth Advisors New York $662M AUM 39.67% 1-Year Est. Return
UCMOK
United Capital Management of KS Salina, Kansas $660M AUM 50.85% 1-Year Est. Return

Decheng Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Decheng Capital held 30 positions worth $466M, up 10% from $422M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Decheng Capital deployed $133M of net new capital in Q4 2024, opening 4 new positions and adding to 10 existing holdings. Its largest new stake was Upstream Bio Inc: 3,285,293 shares worth $54M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Phathom Pharmaceuticals, an estimated $6.88M trimmed.

  • Decheng Capital's largest Q4 2024 buy was Upstream Bio Inc: 3,285,293 shares worth $54M.
  • Decheng Capital added most to CG Oncology in Q4 2024, an estimated $30.5M increase.
  • Decheng Capital's biggest Q4 2024 reduction was Phathom Pharmaceuticals, cutting an estimated $6.88M.
  • Decheng Capital fully exited GeneDx Holdings in Q4 2024, selling an estimated $4.4M.
  • Decheng Capital's ten largest holdings make up 84% of its $466M portfolio in Q4 2024.
  • Decheng Capital opened 4 new positions and closed 2 in Q4 2024.
  • Decheng Capital's portfolio value rose 10% quarter-over-quarter to $466M.

Based on Decheng Capital's 13F filing for Q4 2024, filed 14 Feb 2025.